5,784 Shares in Bioventus Inc. (NYSE:BVS) Bought by Covestor Ltd

Covestor Ltd bought a new position in Bioventus Inc. (NYSE:BVS) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 5,784 shares of the company’s stock, valued at approximately $69,000.

A number of other large investors also recently added to or reduced their stakes in the business. Squarepoint Ops LLC raised its position in Bioventus by 13.8% in the 2nd quarter. Squarepoint Ops LLC now owns 26,171 shares of the company’s stock worth $150,000 after purchasing an additional 3,170 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Bioventus in the first quarter valued at about $28,000. Hillsdale Investment Management Inc. increased its position in shares of Bioventus by 26.1% in the first quarter. Hillsdale Investment Management Inc. now owns 34,742 shares of the company’s stock valued at $181,000 after acquiring an additional 7,200 shares during the period. CWM LLC purchased a new position in shares of Bioventus in the third quarter valued at about $89,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Bioventus in the first quarter valued at about $40,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Trading Down 0.3 %

Shares of BVS opened at $11.13 on Friday. Bioventus Inc. has a 1-year low of $3.64 and a 1-year high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm’s 50-day moving average price is $11.90 and its 200-day moving average price is $8.60. The firm has a market capitalization of $901.20 million, a price-to-earnings ratio of -18.29 and a beta of 0.88.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The business had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same quarter in the previous year, the firm posted $0.05 earnings per share. Sell-side analysts anticipate that Bioventus Inc. will post 0.41 EPS for the current year.

Insider Transactions at Bioventus

In other news, Director John A. Bartholdson bought 25,500 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were purchased at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the purchase, the director now owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. This represents a 0.37 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 32.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Craig Hallum boosted their price objective on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th. Canaccord Genuity Group lifted their target price on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.